Compare Ecolab Inc. (ECL) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs Smith & Nephew plc — how do they compare? Ecolab Inc. trades at $280.22 (market cap $79.79B), while Smith & Nephew plc trades at $29.8 (market cap $12.54B). The key difference: Ecolab Inc. is far larger — about 6.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.65%). Which is the better fit depends on your goals.
| ECL | SNN | |
|---|---|---|
Market Cap | $79.79B | $12.54B |
Sector | Consumer Cyclical | Health |
52-Week High | $308.35 | $38.70 |
52-Week Low | $245.73 | $28.73 |
Enterprise Value | $88.57B | $15.57B |
Dividend Yield | 1.03% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECL trades at $281.17, down 1.14% on the day, with a bullish technical signal from moving averages and strong institutional interest. The company reported Q2 2026 EPS of $2.09, beating estimates, and raised full-year guidance to $8.05-$8.25. Revenue growth remains steady at 5% organic, supported by pricing gains and volume increases. Valuation ratios are elevated with a P/E of 38.21, reflecting premium pricing for consistent performance.
Outlook is positive with a consensus price target of $327.90, implying 16.6% upside. Risks include high valuation sensitivity and rising input costs. The stock offers growth potential from digital expansion and recent CoolIT acquisition, but investors should monitor margin pressures and debt levels.
Smith & Nephew (SNN) trades at $29.76, down 1.06% with bearish technical signals. The company shows improving fundamentals with revenue growth from $5.8B to $6.2B and net income margin expanding to 10.08% in 2025. Recent Q2 2026 earnings beat expectations but the company lowered full-year revenue guidance from 6% to 4% growth due to U.S. Orthopaedics weakness.
While valuation multiples appear reasonable (P/E 20.41, EV/EBITDA 9.9), the stock faces headwinds from mixed earnings performance and cautious analyst sentiment. The primary investment case hinges on execution in robotics and wound care segments offsetting orthopedic challenges, with downside risk from continued U.S. market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
